top of page
32200c5c-7c4c-438f-a9df-3119a2398bf2.png
Autchmaber1.png
ai-cvd.png
AI-CVD Summary
Coronary Calcification
816_aicvd (8)_4_edited.jpg
‌ Aortic Calcification
ٍEpicardial Fat _edited.jpg
Epicardial Fat
816_aicvd (8)_5_edited.jpg
Cardiac Chambers
816_aicvd (8)_7_edited.jpg
Aorta & PA Size
816_aicvd (8)_10_edited.jpg
Lung LAI
816_aicvd (8)_9_edited.jpg
Lung HAI
816_aicvd (8)_11_edited.jpg
Liver Fat
816_aicvd (8)_12_edited.jpg
Muscle & Visceral Fat
816_aicvd (8)_13_edited.jpg
Bone Density
f055739f-1956-41a1-8156-cda95d1fea9f.png
AI-CVD Bundle
Muscle and Fat Analysis.png
Liver Attenuation.png
Cardiac Chambers Volumetry.png
ٍEpicardial Fat .png
Bone Mineral Density (BMD) .png
coronaryArteryCalcification.png
Lung Density Report- High Attenuation Index.png
Thoracic Aorta and Pulmonary Artery Sizing .png
Aortic Wall Aortic and Mitral Valve Report.png
Lung Density Report- Low Attenuation Index.png
AI-CVD--.png
Frame 1000008286.png
Frame 1000008286.png

Agatston-2.0: A New Generation of AI-Based Coronary Calcium Analysis

Jul 15
1 min read

Updated: Jul 17



Agatston-2.0 is a next-generation artificial intelligence framework developed to enhance cardiovascular risk assessment in individuals with Agatston coronary artery calcium (CAC) scores below 100—a population that represents nearly 75% of individuals undergoing CAC scanning and accounts for a substantial proportion of future coronary heart disease events.

Rather than relying solely on conventional calcium scoring, Agatston-2.0 introduces advanced AI-derived biomarkers that analyze the distribution, density, and spatial characteristics of coronary calcification. By combining these novel imaging biomarkers with additional AI-CVD cardiometabolic measurements—including cardiac chamber volumes, visceral fat, and epicardial fat—the platform provides a more comprehensive evaluation of cardiovascular risk.

The presented data demonstrate that Agatston-2.0 can identify high-risk individuals who would otherwise be classified as low risk by traditional CAC scoring alone. The AI-based approach also shows strong correlation with coronary plaque burden on coronary CT angiography (CCTA), enabling more accurate risk stratification and supporting earlier preventive intervention.

This presentation highlights the scientific foundation, AI methodology, validation studies, and clinical implications of Agatston-2.0, illustrating how artificial intelligence can redefine the role of coronary calcium scoring in modern preventive cardiology.

Download the complete presentation below to explore the full workflow, validation results, and clinical evidence behind Agatston-2.0.




Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png
autoliver patent.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page